CTRP6 which can be used as therapeutic and prophylactic agent for autoimmune diseases
AssigneeThe University of Tokyo
InventorsYoichiro Iwakura, Masanori Murayama, Harumichi Ishigame, Shigeru Kakuta
Life of this patent
Estimating the term…
Abstract
Provided are methods of suppressing complement alternative pathway in a mammalian subject in need thereof, comprising administering to said subject a therapeutically effective amount of C1q and tumor necrosis factor related protein 6 (CTRP6) or a functional analog thereof.
Claims13
A method of suppressing complement alternative pathway in a mammalian subject in need thereof, comprising administering to the subject a therapeutically effective amount of C1 q and tumor necrosis factor related protein 6 (CTRP6) or a functional analog thereof, wherein the CTRP6 or functional analog comprises the amino acid sequence selected from the group consisting of:
- a) human CTRP6 (SEQ ID NO:
- 1);
- and
- b) the amino acid sequence having at least 95% sequence identity with C1 q domain of human CTRP6 and activity to suppress complement activation.
A method of suppressing complement alternative pathway in a mammalian subject in need thereof, comprising administering to the subject a therapeutically effective amount of C1q and tumor necrosis factor related protein 6 (CTRP6) or a functional analog thereof, wherein the CTRP6 or functional analog comprises the amino acid sequence selected from the group consisting of:
- a) human CTRP6 (SEQ ID NO:
- 1);
- b) the amino acid sequence having at least 95% sequence identity with human CTRP6 and activity to suppress complement activation;
- and c) the amino acid sequence having at least 95% sequence identity with C1q domain of human CTRP6 and activity to suppress complement activation.
A method of suppressing complement alternative pathway in a mammalian subject in need thereof, comprising administering to the subject a therapeutically effective amount of a functional analog of C1q and tumor necrosis factor related protein 6 (CTRP6), wherein the functional analog comprises the amino acid sequence having at least 95% sequence identity with C1q domain of human CTRP6 and activity to suppress complement activation.
Dependencies are inferred from the claim text.